Due to the elicited increase in plasma bilirubin, albumin administration to reduce bilirubin-induced neurological damage invalidates the use of plasma TB as an indicator of the overall risk of bilirubin neurotoxicity. This evidence concerns the gene ALB and tuberculosis.